1. Home
  2. ELA vs PRME Comparison

ELA vs PRME Comparison

Compare ELA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envela Corporation

ELA

Envela Corporation

HOLD

Current Price

$14.07

Market Cap

365.3M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.69

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELA
PRME
Founded
1965
2019
Country
United States
United States
Employees
276
N/A
Industry
Consumer Specialties
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.3M
553.2M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
ELA
PRME
Price
$14.07
$3.69
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$16.50
$7.56
AVG Volume (30 Days)
128.4K
2.5M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
115.38
18.18
EPS
0.50
N/A
Revenue
$241,021,362.00
$4,632,000.00
Revenue This Year
N/A
$7.06
Revenue Next Year
$22.54
$47.01
P/E Ratio
$27.46
N/A
Revenue Growth
33.62
55.28
52 Week Low
$7.02
$2.67
52 Week High
$29.68
$6.94

Technical Indicators

Market Signals
Indicator
ELA
PRME
Relative Strength Index (RSI) 18.21 57.51
Support Level $11.39 $3.16
Resistance Level $13.87 $3.69
Average True Range (ATR) 0.61 0.24
MACD 0.16 0.04
Stochastic Oscillator 13.78 87.86

Price Performance

Historical Comparison
ELA
PRME

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: